End Users
CRC BID has a strong focus on the needs of its end users. The end users of the CRC's outputs may be broadly categorised as clinicians, researchers, engineers and technicians in public and private biomedicine and the commercial entities able to bring these outputs to market as saleable products and services.
Needs
The needs of end users in the market segment known as functional and structural medical imaging include the following:
|
|
· |
New and improved radiopharmaceutical tracers with high specificity for cancer and neurological diseases, together with chemical processes for their on-site synthesis |
|
|
· |
New detectors capable of significantly improved sensitivity and resolution of new and improved tracers in PET and other nuclear medicine imaging systems; |
|
|
· |
New detectors capable of significantly improved sensitivity and resolution in traditional modalities such as radiography (X-ray) and computer tomography (CT) to significantly enhance their structural imaging capability, as well as better X-ray detectors for facilities such as synchrotron beamlines; |
|
|
· |
Improved Australian capability and capacity for small-animal and clinical trials to determine the efficacy of new drugs for their intended use. |
Value
The planned outputs of the CRC's work in biomedical imaging offer substantial commercial potential for Australia.
The major sources of revenue over the period to 2015 are expected to include sales revenue from radiotracer synthesis units, detector subsystems for PET and X-ray systems, as well as income from clinicial trials undertaken in Australia.
Savings
In addition to the potential commercial opportunities, outlined above, the outputs of the CRC are expected to produce significant cost savings in disease diagnosis and treatment and help reduce the indirect cost of disease-related mortality.
While many disease groups are expected to benefit from advances in biomedical imaging, three in particular are likely to gain a substantial benefit: cancer, and neurological disorders such as epilepsy and stroke.
According to the Australian Institute of Health and Welfare, these three disease groups comprise more than a quarter of total health spending in Australia and contribute almost three-quarters of all deaths.
In general, significant savings are expected in healthcare costs through lower drug costs and lower in-patient and out-patient costs. In the three disease groups mentioned above, substantial annual savings are considered feasible.
> Go to IP Management
